Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 123

1.

Mesenchymal Stem Cell-Induced DDR2 Mediates Stromal-Breast Cancer Interactions and Metastasis Growth.

Gonzalez ME, Martin EE, Anwar T, Arellano-Garcia C, Medhora N, Lama A, Chen YC, Tanager KS, Yoon E, Kidwell KM, Ge C, Franceschi RT, Kleer CG.

Cell Rep. 2017 Jan 31;18(5):1215-1228. doi: 10.1016/j.celrep.2016.12.079.

2.

MMTV-cre;Ccn6 knockout mice develop tumors recapitulating human metaplastic breast carcinomas.

Martin EE, Huang W, Anwar T, Arellano-Garcia C, Burman B, Guan JL, Gonzalez ME, Kleer CG.

Oncogene. 2017 Apr 20;36(16):2275-2285. doi: 10.1038/onc.2016.381. Epub 2016 Nov 7.

PMID:
27819674
3.

Atypical Apocrine Adenosis: Diagnostic Challenges and Pitfalls.

Asirvatham JR, Falcone MM, Kleer CG.

Arch Pathol Lab Med. 2016 Oct;140(10):1045-51. doi: 10.5858/arpa.2016-0238-RA. Review.

PMID:
27684975
4.

ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.

Hertz DL, Henry NL, Kidwell KM, Thomas D, Goddard A, Azzouz F, Speth K, Li L, Banerjee M, Thibert JN, Kleer CG, Stearns V, Hayes DF, Skaar TC, Rae JM.

Physiol Genomics. 2016 Sep 1;48(9):688-98. doi: 10.1152/physiolgenomics.00065.2016. Epub 2016 Aug 19.

PMID:
27542969
5.

Dual roles of CCN proteins in breast cancer progression.

Kleer CG.

J Cell Commun Signal. 2016 Sep;10(3):217-222. Epub 2016 Aug 12.

6.

Phyllodes Tumor of the Breast: Histopathologic Features, Differential Diagnosis, and Molecular/Genetic Updates.

Zhang Y, Kleer CG.

Arch Pathol Lab Med. 2016 Jul;140(7):665-71. doi: 10.5858/arpa.2016-0042-RA. Review.

PMID:
27362571
7.

Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression.

Zhang Y, Liss AL, Chung E, Pierce LJ, Kleer CG.

Breast Cancer Res Treat. 2016 Jul;158(1):21-8. doi: 10.1007/s10549-016-3853-5. Epub 2016 Jun 11.

PMID:
27290698
8.

Chronic Mastitis in Egypt and Morocco: Differentiating between Idiopathic Granulomatous Mastitis and IgG4-Related Disease.

Allen SG, Soliman AS, Toy K, Omar OS, Youssef T, Karkouri M, Ayad E, Abdel-Aziz A, Hablas A, Tahri A, Oltean HN, Kleer CG, Merajver SD.

Breast J. 2016 Sep;22(5):501-9. doi: 10.1111/tbj.12628. Epub 2016 Jun 8.

PMID:
27279578
9.

The matricellular protein CCN6 (WISP3) decreases Notch1 and suppresses breast cancer initiating cells.

Huang W, Martin EE, Burman B, Gonzalez ME, Kleer CG.

Oncotarget. 2016 May 3;7(18):25180-93. doi: 10.18632/oncotarget.7734.

10.

Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers.

Yang CC, LaBaff A, Wei Y, Nie L, Xia W, Huo L, Yamaguchi H, Hsu YH, Hsu JL, Liu D, Lang J, Du Y, Lien HC, Li LY, Deng R, Chan LC, Yao J, Kleer CG, Hortobagyi GN, Hung MC.

Am J Transl Res. 2015 Jun 15;7(6):1009-20. eCollection 2015.

11.

Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer.

Toy KA, Valiathan RR, Núñez F, Kidwell KM, Gonzalez ME, Fridman R, Kleer CG.

Breast Cancer Res Treat. 2015 Feb;150(1):9-18. doi: 10.1007/s10549-015-3285-7. Epub 2015 Feb 10.

12.

Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.

Cani AK, Hovelson DH, McDaniel AS, Sadis S, Haller MJ, Yadati V, Amin AM, Bratley J, Bandla S, Williams PD, Rhodes K, Liu CJ, Quist MJ, Rhodes DR, Grasso CS, Kleer CG, Tomlins SA.

Mol Cancer Res. 2015 Apr;13(4):613-9. doi: 10.1158/1541-7786.MCR-14-0578. Epub 2015 Jan 15.

13.

A 3D matrix platform for the rapid generation of therapeutic anti-human carcinoma monoclonal antibodies.

Dudley DT, Li XY, Hu CY, Kleer CG, Willis AL, Weiss SJ.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14882-7. doi: 10.1073/pnas.1410996111. Epub 2014 Sep 29.

14.

Characterization of type III TGF-β receptor expression in invasive breast carcinomas: a potential new marker and target for triple negative breast cancer.

Pang JC, Virani NK, Kidwell KM, Kleer CG.

J Cell Commun Signal. 2014 Sep;8(3):211-8. doi: 10.1007/s12079-014-0240-z. Epub 2014 Aug 19.

15.

Re-excision rates of invasive ductal carcinoma with lobular features compared with invasive ductal carcinomas and invasive lobular carcinomas of the breast.

Arps DP, Jorns JM, Zhao L, Bensenhaver J, Kleer CG, Pang JC.

Ann Surg Oncol. 2014 Dec;21(13):4152-8. doi: 10.1245/s10434-014-3871-7. Epub 2014 Jul 1.

PMID:
24980090
16.
17.

SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model.

Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol N, Clouthier SG, Malik F, Paulson AK, D'Angelo RC, Korkaya S, Baker TL, Esen ES, Prat A, Liu S, Kleer CG, Thomas DG, Wicha MS, Korkaya H.

Oncogene. 2015 Feb 5;34(6):671-80. doi: 10.1038/onc.2014.4. Epub 2014 Feb 17.

18.

EZH2 expands breast stem cells through activation of NOTCH1 signaling.

Gonzalez ME, Moore HM, Li X, Toy KA, Huang W, Sabel MS, Kidwell KM, Kleer CG.

Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3098-103. doi: 10.1073/pnas.1308953111. Epub 2014 Feb 10.

19.

Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity.

Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, D'Alessio AC, Young RA, Weinberg RA.

Cell. 2013 Jul 3;154(1):61-74. doi: 10.1016/j.cell.2013.06.005.

20.

EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer.

Knudsen ES, Dervishaj O, Kleer CG, Pajak T, Schwartz GF, Witkiewicz AK.

Cell Cycle. 2013 Jul 1;12(13):2042-50. doi: 10.4161/cc.25065. Epub 2013 Jun 6.

Supplemental Content

Loading ...
Support Center